Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 16/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 10/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5476309 | 0.83 | SOS2 (0.44) | ADRB3ADRB2ADRB1POLBMEN1 | |
| SCHEMBL5479233 | 0.81 | ADRB3 (0.54) | ADRB3ADRB2ADRB1POLBMEN1 | |
| SCHEMBL5485060 | 0.81 | ADRB3 (0.54) | ADRB3ADRB2ADRB1POLBMEN1 | |
| SCHEMBL5482928 | 0.80 | ADRB3 (0.60) | ADRB3ADRB2ADRB1 | |
| SCHEMBL14527176 | 0.80 | MTNR1A (0.40) | ADRB3ADRB2ADRB1POLBMEN1 | |
| SCHEMBL6227137 | 0.78 | ADRB3 (0.59) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6227144 | 0.78 | ADRB3 (0.59) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6227133 | 0.78 | ADRB3 (0.59) | ADRB3ADRB2ADRB1 | |
| Trifluoroacetic Acid SCHEMBL6224739 | 0.77 | ADRB3 (0.74) | ADRB3ADRB2ADRB1 | |
| SCHEMBL5480811 | 0.75 | ADRB3 (0.60) | ADRB3ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217724-B2 | Indole, indazole, and benzazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20060063762-A1 | Indole indazole and benzazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2006-03-23 | — | — | US | disclosed |
| EP-1514869-A1 | INDOLE, INDAZOLE, AND BENZAZOLE DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063762-A1 | Indole indazole and benzazole derivative | ADRB3, ADRA2C, ADRB2 | ADRB3 1/4885ADRB2 3/4885ADRB1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.